BioMarin rated at buy by Merrill

Merrill Lynch analyst Tom McGahren rated BioMarin Pharmaceutical Inc. at a buy after the company announced Aldurazyme was approved in Japan with orphan-drug status for the treatment of mucopolysaccharidosis I (MPS I), one of the rare lysosomal storage diseases. Third-quarter 2006 Aldurazyme sales of $25 million were reported by joint venture partner Genzyme. Shares of the Novato, Calif.-based biopharmaceutical company were down 32 cents, or 2.00%, at $15.71. (Nasdaq: BMRN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.